
Messoud Ashina
Institution: | Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen |
City: | Copenhagen |
Country: | Denmark |
Biography
Professor Messoud Ashina is Professor of Neurology and Director of the Human Migraine Research Unit at the Department of Neurology & Danish Headache Center, Rigshospitalet, the University of Copenhagen, Denmark. He is Past President of the International Headache Society (2019–2021) and is Past General Secretary of the European Headache Federation. Prof. Ashina is a Fellow of the European Academy of Neurology. In addition, he is an Associate Editor of Cephalalgia, an Associate Editor of The Journal of Headache and Pain, and an Associate Editor of Brain
Prof. Ashina’s research interests include the pathophysiology of migraine and mechanisms of action of antimigraine medications, as well as experimental migraine models, functional neuroimaging, and novel antimigraine drug targets. He has authored over 600 papers, abstracts and book chapters on the topic of headache, including migraine and cluster headache.
Having obtained his MD from the Azerbaijan Medical University, Prof. Ashina went on to complete his residency in neurology at the University of Copenhagen, where he gained his PhD and DMSc. In the past, he has served as President of the Danish Headache Society.
Disclosures
Employment: Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Denmark
Society Leadership/Board: Past President-International Headache Society
Personal fees: AbbVie, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Pfizer, and Teva
Research support: Danish National Research Foundation, Lundbeck Foundation, Novo Nordisk Foundation, Novartis, and Lundbeck
Data Safety Monitoring Board/Advisory Board: AbbVie, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Pfizer, and Teva
Clinical trials involvement: Ongoing AbbVie, Lundbeck and Pfizer
Relationship with scientific journals: Associate Editor: The Journal of Headache and Pain and Brain; Editorial Board of Neurotorium and has received honoraria
Commercial interests: None